{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Apolizumab",
  "nciThesaurus": {
    "casRegistry": "267227-08-7",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro. ",
    "fdaUniiCode": "G88KCP51RE",
    "identifier": "C2228",
    "preferredName": "Apolizumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [],
    "synonyms": [
      "1D10 Anti-lymphoma Antibody",
      "APOLIZUMAB",
      "Apolizumab",
      "MAbHu1D10",
      "MoAb Hu1D10",
      "MoAb: Hu1D10",
      "Monoclonal Antibody Hu1D10",
      "Monoclonal antibody 1D10",
      "Remitogen",
      "apolizumab"
    ]
  }
}